Dr. Mike Burgess, senior vice president of discovery medicine and clinical pharmacology at Bristol-Myers Squibb Co. and the head of the company's cardiovascular, fibrosis, immunoscience and genetically defined diseases (GDD) development teams, discusses why BMS is investing in areas outside of its core oncology expertise and what data readouts to expect from the company's CV and fibrosis pipeline next year. He also warns about the consequences of narrow R&D visions and being unprepared for exciting new scientific developments to suffer setbacks in early development.
Burgess, who is based in Princeton, New Jersey, joined BMS as a senior VP in January 2013 from fellow big pharma company Roche, where he had held positions since 2008 and most
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?